KRAS and lung cancer: In one study, imaging mass cytometry revealed a dramatic remodeling of the TME in a “cold” model of lung cancer upon KRAS inhibition involving expansion of a macrophage subset found exclusively within the tumor domain, which interacted with fibroblasts and expressed markers of antigen-presentation including CD86 and MHC-II (84).